

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 58044

Manuscript Type: ORIGINAL ARTICLE

Observational study

No significant association between Dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19

Jiang-Hua Zhou, Bin Wu, Wen-Xin Wang, Fang Lei, Xu Cheng, Juan-Juan Qin, Jing-Jing Cai, Xiao-Jing Zhang, Feng Zhou, Ye-Mao Liu, Hao-Miao Li, Li-Hua Zhu, Zhi-Gang She, Xin Zhang, Juan Yang, Hong-Liang Li

Abstract

Match Overview

1	Internet 72 words crawled on 05-Jul-2020 www.seme.org	2%
2	Internet 31 words crawled on 31-Aug-2020 eprints.gla.ac.uk	1%
3	Crossref 12 words Lihua Zhu, Zhi-Gang She, Xu Cheng, Juan-Juan Qin et al. "Association of Blood Glucose Control and Outcomes in F...	<1%
4	Crossref 11 words Xu Cheng, Ye-Mao Liu, Haomiao Li, Xin Zhang et al. "Metf ormin Is Associated with Higher Incidence of Acidosis, bu...	<1%
5	Internet 11 words crawled on 20-Aug-2020 www.researchsquare.com	<1%
6	Internet 10 words crawled on 11-Sep-2020 www.frontiersin.org	<1%
7	Internet 10 words crawled on 11-Sep-2018	<1%

No significant association between Dipeptidyl peptidase-4 inhibito



ALL

IMAGES

VIDEOS

74,200 Results

Any time ▼

Exposure to dipeptidyl–peptidase–4 inhibitors and COVID–19 ...

<https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14097>

Proportion of **dipeptidyl–peptidase–4 inhibitor** (DPP–4i) users among **COVID–19** patients with diabetes and control groups. The combination of clinical conditions in the various groups are illustrated by the table (+ for presence; – for absence). T2D, type 2 diabetes

Cited by: 1

Author: Gian Paolo Fadini, Mario Luca Morieri, E...

Publish Year: 2020

Association between dipeptidyl peptidase-4 inhibitor drugs ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728794>

Previous studies have reported conflicting results for the relationship between dipeptidyl peptidase-4 (DPP-4) inhibitor drugs and acute pancreatitis. The aim of this study was to investigate the association between DPP-4 inhibitors and an increased risk of **acute pancreatitis using meta-analysis**.

Cited by: 2

Author: Shimin Chen, Enfa Zhao, Wenfei Li, Jieh...

Publish Year: 2017

Assessing the association between dipeptidyl peptidase-4 ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997957>

This association between DPP4i use and diagnosis of celiac disease is biologically plausible. **Gluten** is a substrate for DPP-4, which removes N-terminal proline residues. HLA-DQ2 preferentially binds peptides with an N-terminal proline 1 ; therefore, inhibition of DPP-4 may potentiate celiac disease by facilitating presentation of gluten peptides by HLA-DQ.

Author: Dandan Li, Jocelyn Anne Silvester, ...

Publish Year: 2020

Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory ...

<https://care.diabetesjournals.org/content/42/7/e119> ▼

Jul 01, 2019 · A recent retrospective cohort study found that new use of dipeptidyl peptidase 4 inhibitors (DPP4i) of 1.6 years was associated with an **increased risk of inflammatory bowel**

[国内版](#)[国际版](#)

No significant association between dipeptidyl peptidase-4 inhibitors and

[Chat with Bing](#)[Sign in](#)

Microsoft Bing

[ALL](#)[IMAGES](#)[VIDEOS](#)

81,300 Results

Any time ▼

Assessing the association between dipeptidyl peptidase-4 ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997957>

Introduction. **Dipeptidyl peptidase 4** (DPP4) enzyme is an endoprotease that removes N-terminal prolines from intestinal peptides. 1 These peptides include glucagon-like peptide-1 (GLP-1), which, as one of the main human incretin hormones produced by the gastrointestinal system, enhances insulin secretion in a glucose-dependent manner. 2 Inhibition of DPP4 thus raises GLP-1 levels and has a ...

Author: Dandan Li, Jocelyn Anne Silvester, M... **Publish Year:** 2020

Diabetes in COVID-19: Prevalence, pathophysiology ...

<https://www.sciencedirect.com/science/article/pii/S1871402120300631>

Jul 01, 2020 · Background and aims. High prevalence of diabetes makes it an important comorbidity in patients with **COVID-19**. We sought to review and analyze the data regarding the **association between** diabetes and **COVID-19**, pathophysiology of the disease in diabetes and management of patients with diabetes who develop **COVID-19** infection.

Cited by: 84

Author: Awadhesh Kumar Singh, Ritesh Gupta, A...

Search Tools

[Turn off Hover Translation \(关闭取词\)](#)



No significant association between dipeptidyl peptidase-4 inhibitor



ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

81,400 Results

Any time ▾

[Assessing the association between dipeptidyl peptidase-4 ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997957>

Introduction. **Dipeptidyl peptidase 4** (DPP4) enzyme is an endoprotease that removes N-terminal prolines from intestinal peptides. 1 These peptides include glucagon-like peptide-1 (GLP-1), which, as one of the main human incretin hormones produced by the gastrointestinal system, enhances insulin secretion in a glucose-dependent manner. 2 Inhibition of DPP4 thus raises GLP-1 levels and has a ...

Author: Dandan Li, Jocelyn Anne Silvester, M... **Publish Year:** 2020

[Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory ...](#)

<https://care.diabetesjournals.org/content/42/7/e119> ▾

Jul 01, 2019 - A recent retrospective cohort study found that new use of **dipeptidyl peptidase 4 inhibitors** (DPP4i) of 1.6 years was associated with an increased risk of inflammatory bowel disease (IBD) compared with other antidiabetes medications (hazard ratio 1.75 (95% CI 1.22, 2.49) (1). We previously demonstrated a weak **association** in an analysis of 86 prevalent and incident cases of IBD ...

Cited by: 3 **Author:** Guangyao Li, Guangyao Li, Matthew J. C...

Publish Year: 2019

[Diabetes in COVID-19: Prevalence, pathophysiology ...](#)

<https://www.sciencedirect.com/science/article/pii/S1871402120300631>

Jul 01, 2020 - Background and aims. High prevalence of diabetes makes it an important comorbidity in patients with **COVID-19**. We sought to review and analyze the data regarding the **association between** diabetes and **COVID-19**, pathophysiology of the disease in diabetes and management of patients with diabetes who develop **COVID-19** infection.

Cited by: 84 **Author:** Awadhesh Kumar Singh, Ritesh Gupta, A...

Publish Year: 2020

[Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory ...](#)

<https://care.diabetesjournals.org/content/42/11/2065> ▾

Nov 01, 2019 - While a **meta-analysis of randomized trials** suggests no association between DPP4i and IBD risk, a **disproportionality analysis of the U.S. Food and Drug Administration Adverse Event Reporting System** database suggested a weak to moderate signal of CD; the reporting odds ratio (≥ 2

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997957> termed as a positive signal) was 2.63 (95% CI 1.74–3.99) compared with a comparator group ...